Karel Honegr

Learn More
BACKGROUND A new trivalent inactivated split-virus influenza vaccine (TIV) was recently introduced in the United States. We assessed the efficacy of TIV against culture-confirmed influenza A and/or B. METHODS In this double-blind trial conducted from September 2006 to May 2007 in the Czech Republic and Finland, participants aged 18-64 years were(More)
BACKGROUND Our aim was to determine the efficacy of a trivalent inactivated split virus influenza vaccine (TIV) against culture-confirmed influenza A and/or B in adults 18 to 64 years of age during the 2005/2006 season in the Czech Republic. METHODS 6203 subjects were randomized to receive TIV (N = 4137) or placebo (N = 2066). The sample size was based on(More)
To determine the minimum vaccine potency per intradermal dose required to elicit an adequate immune response using the Thai Red Cross (TRC) regimen (2-2-2-0-1-1), healthy volunteers received 0.1 mL volumes of PCECV containing decreasing amounts of antigen. Subjects also received HRIG to evaluate potential interference with antibody production. Results(More)
Neuroborreliosis is a form of borreliosis that affects the central and/or peripheral nervous system. Although it can mimic neurologic and ophthalmologic disorders such as multiple sclerosis and optic neuritis, visual evoked potential (VEP) examination is usually not used in neuroborreliosis diagnostics. Combined VEP testing (pattern-reversal VEPs and VEPs(More)
This is a case report on a 50-year-old patient, working as a forest guard in a high-endemic region. The subject was immunized with two doses of FSME Immun 0.5 Baxter vaccine (with a time interval of 18 days between the two doses). Approx. two months after the second vaccination the subject developed symptoms of Tick-borne encephalitis. Clinical course and(More)
Survey of criteria necessary to establish the diagnosis of Lyme disease according to its definitions by various organizations and institutions in the USA and Europe (European Union Concerted Action on Lyme Borreliosis, Centers for Disease Control and Prevention, The International Lyme and Associated Diseases Society). In the discussion the authors present(More)
Using a commercial kit for the examination of recombinant immunoblot the authors examined sera of 85 patients with direct evidence of Borrelia burgdorferi sensu lato in serum or cerebrospinal fluid or patients with typical dermal form of borreliosis. The results were compared with results of assessment of specific antibodies by the ELISA test. The authors(More)
The diagnosis of Lyme disease in 18 patients has been proved by detection of Borrelia burgdorferi sensu lato when using immunoelectron microscopy or detecting its nucleic acid by PCR in the plasma or the cerebrospinal fluid. The positive results occurred in the plasma or in the cerebrospinal fluid in the period of 4-68 months after an antibiotic treatment.(More)
BACKGROUND Antiborrelia antibodies in Lyme borreliosis (LB) are mostly detected by enzyme immunoassay (EIA), confirmed by immunoblot (the "two-step system"). In indicated cases, direct evidence of Borrelia burgdorferi is obtained with the PCR method, electron microscopy and cultivation. The "one-step system" of testing for IgM and IgG antibodies in LB is(More)
In 18 patients with Lyme borreliosis the authors proved the persistence of Borrelia burgdorferi sensu lato by detection of the causal agent by immune electron microscopy or of its DNA by PCR in plasma or cerebrospinal fluid after an interval of 4-68 months. Clinical manifestations common in Lyme borreliosis were present in only half the patients, in the(More)